Alzamend Neuro, Inc. (ALZN)

NASDAQ: ALZN · IEX Real-Time Price · USD
0.900
-0.027 (-2.94%)
At close: Jun 28, 2022 4:00 PM
0.925
+0.025 (2.789%)
After-hours: Jun 28, 2022 7:55 PM EDT

Company Description

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders.

Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's.

The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Alzamend Neuro, Inc.
Country United States
Founded 2016
IPO Date Jun 15, 2021
Industry Biotechnology
Sector Health Care
Employees 3

Contact Details

Address:
3802 Spectrum Blvd,
Tampa, Florida 33612
United States
Phone 844 722 6333
Website alzamend.com

Stock Details

Ticker Symbol ALZN
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency US Dollars
IPO Price $5.00
CIK Code 1677077
ISIN Number US02262M3088
SIC Code 2834

Key Executives

Name Position
Stephan Jackman Chief Executive Officer and Director
Henry C. W. Nisser Esq. Executive Vice President, General Counsel and Director
Kenneth S. Cragun CPA Senior Vice President of Finance
Milton Charles Ault III Founder and Chairman Emeritus
Lien T. Escalona Chief Financial Officer
David J. Katzoff Chief Operating Officer

Latest SEC Filings

Date Type Title
Jun 28, 2022 8-K Current report
Jun 21, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities
Jun 8, 2022 4 Statement of changes in beneficial ownership of securities
Jun 6, 2022 8-K Current report
Jun 3, 2022 4 Statement of changes in beneficial ownership of securities
May 31, 2022 4 Statement of changes in beneficial ownership of securities
May 26, 2022 4 Statement of changes in beneficial ownership of securities